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ABSTRACT
Flavonoids are a long and well known class of natural products. Their potential health
benefits can be attributed to their antioxidant activity, and modulation of cell signaling
pathways. Green tea one of the most widely consumed beverages, consist of flavonoids
such as catechins and tannins. Epigallocatechin gallate (EGCG) the major catechin of
green tea exhibits multiple health benefits due to its antioxidant nature. The radical
scavenging activity of EGCG is attributed to its structure. Therefore, a study on
molecular features of EGCG would provide valuable information on structural
modifications, which may change the physiochemical properties such as bioavailability
and solubility.
Although flavonoids are abundant and commercially available they are difficult to
purify and crystallize. In this respect, crystallizing EGCG was challenging. By exploring
different techniques EGCG was crystallized. Here in this study one new form of EGCG
and two solvates, acetonitrile and nitrobenzene, have been synthesized and structurally
characterized by differential scanning calorimetry (DSC), infrared (IR) and powder X-ray
diffraction (PXRD). The crystal structures were solved by single-crystal X-ray
diffraction and a detailed description of synthesis and about the supramolecular synthons
that exist in these crystal forms are given.

x

1. INTRODUCTION
1.1 Flavonoids
1.1.1 History
Flavonoid compounds, which are ubiquitous in nature, occupy a prominent position
among the plant phenols. Though flavonoids are present in other parts of plants, many
flavonoids are easily recognized as flower pigments in most angiospermic plants. 3
Flavonoids are distributed in higher plants, bacteria, algae, fungi, and animals. The
earliest suggestion that substances existed in nature that would eventually be recognized
as flavonoids can be traced back to the 17th century. In 1682 Nehemiah Grew discussed
the differences between the solubility properties of pigments, which can be recognized as
the starting point for naturally occurring compounds. 1 Flavonoids are responsible for
coloration of the plants. Autumn coloration of leaves has attracted the attention of many
workers for years. Anthocyanin pigments have played a major role in the history of
naturally occurring compounds.
The term “flavone” first appeared in a paper by Kostanecki and Tambor (1895). 1 In
1893 De Larie and Tiemann obtained the first isoflavone from the rhizomes of “Iris
Florentina”. The first flavanone recognized as naturally occurring was butrin 1 and the
first isoflavanoid discovered structurally is “Prunetin” described by Finnamore (1910). 1

1

St.Von Kostanecki first established the basic structure of the flavones and synthesized a
number of natural compounds. 2 In a continuation to these studies, Herzig and A.G Perkin
determined the positions of attachment of sugar residues in the glycosides. 2 Out of all
the flavonoids, anthocyanins are the first compounds which were studied in detail. This is
due to their wide abundance in nature as a coloring compound in plants.
1.1.2 Structure
Flavonoids are based on a 15 carbon atom skeleton. A simple way to describe the
flavonoid skeleton is, two phenyl rings connected by three carbon-bridges. It can also be
represented as C6 – C3 – C6.

Figure 1.1: Skeleton of Flavonoid

The chemical structure of the flavonoids are based on a C15 skeleton with a chromane
ring bearing a second aromatic ring B in position 2,3 or 4. 3

Figure 1.2: Structural representation of Flavonoids

2

In certain flavonoids the C ring is either in an open form or replaced by a five
membered ring (eg: aurones).
1.1.3 Classification of Flavonoids

Figure 1.3: Chalcone

Figure 1.4: Skeleton of Flavone

Figure 1.5: Quericetol

Figure 1.6: Skeleton of Flavanone

Figure 1.7: Anthocyanins

Figure 1.8: Skeleton of Isoflavonoid

3

Figure 1.9: Skeleton of Neoflavonoids

Flavonoids are classified according to the substitution pattern of the C-ring. The
oxidation state of the heterocyclic ring and the position of the B ring are also considered
in classifying flavonoids. There are 6 major sub groups of flavonoids. 3
Chalcones, (Fig: 1.3) the first sub class of flavonoids contain three carbons – bridge
in open form. 5 Flavones (Fig: 1.4) are based on the backbone of 2-phenylchromen-4-one
(2-phenyl-1-benzopyran-4-one). Generally, found in herbaceous families like Labiatae,
Umbellifereae, and Compositae etc.

3, 4

Flavanols (Fig: 1.5) contain a hydroxyl group at

C-3 position (Eg: Quericetol). In flavanone (Fig: 1.5) the hydroxyl group at C-3 position
is absent. Anthocyanins (Fig: 1.6) are considered as major class of pigments. Isoflavanoid
(Fig: 1.7) are isomeric to flavones by virtue of their having the B-ring attached to
position-3 rather than position-2 as in flavones. 1, 3 Neoflavonoids (Fig1.8) contain B-ring
in 4th position. Derived from the 4-phenylcoumarine (4-phenyl-1, 2-benzopyrone)
structure. 3, 6

4

1.1.4 Occurrence and distribution of Flavonoids
Although flavonoids are widely distributed in nature and in foods, they lack uniform
distribution throughout the plant kingdom. Flavonoid compounds occur in all parts of the
higher plants: roots, stems, leaves, flowers, pollen, fruit, seeds, wood and bark. Ferns
contain many flavonoid compounds of the types found in flowering plants.

2

Different

food items contain varying concentrations of flavonoids. Teas, fruits, and dark chocolates
contain moderate to high concentrations of flavonoids. Vegetables like broccoli and
some fruit juices like cranberry and orange provide low levels of flavonoid content. Black
and oolong tea contents have high contents of derived tannins. 7
1.1.5 Extraction and Purification
Different parameters effect the extraction of the flavonoids from plant materials;
their chemical nature, storage time and conditions, and the presence of interfering
substances. The solubility of the flavonoids depend upon the polarity of the solvent used,
degree of polymerization, interaction with other food constituents and formation of
insoluble complexes. There is no uniform or completely satisfactory procedure that is
suitable for extraction of all flavonoids or specific type of flavonoids in plant materials.
The most commonly used solvents in extraction of these compounds are methanol, ethyl
acetate, acetone, and water, their combinations are also used. Propanol and
dimethylformamide, are also used but to a lesser extent. Extraction period usually varies
from 1min to 24 hrs.

5

Extraction of polyphenols from food constituents also depends on sample-solvent ratio.
The Flavonoid extracts can be partially purified, using ion exchange resins. Extracts
can also be purified and fractioned by using solid phase extraction or solid phase
microextraction (SPME), and column chromatography. Different columns are used for
extraction of flavonoids, like C-18 column, Sephadex column etc. Recently counter
current chromatography (CCC) has been used as an alternative to liquid chromatography
for fractionation of various flavonoids. High speed centrifugal countercurrent
chromatography is used in the separation of flavonoids like tea catechins, anthocyanins,
theaflavins, etc. 8
Quantification of flavonoids is carried out by different spectroscopic techniques. Gas
Chromatography (GC) and high performance liquid chromatography (HPLC) are widely
used in separation and quantitation of flavonoids. Structure elucidation is carried out by a
combination of GC or HPLC with mass spectrometry and also various other relevant
techniques. 8
1.1.6 Uses
Due to their beneficial health effects, flavonoids have garnered more interest in the
past 2 decades. It was initially hypothesized that pharmacological effects of flavonoids
would be related to their antioxidant activity, but the available evidence from cell culture
experiments suggested that modulation of cell signaling pathway by flavonoids was
attributed to their most of the biological effects. Studies in cell cultures have suggested
that flavonoids may affect the chronic disease by inhibiting the kinases. 115

6

Flavonoids have a wide range of beneficial health effects such as, reducing the risk of
cancer, 116,117 anti-inflammatory, 118 reducing the risk of developing diabetes mellitus, 119
infertility,

120

anticholesterolemia,

121

antiatherosclerosis,

121

antiulcer, ability to inhibit

human platelet aggregation, 123 reducing the skin wrinkling, and also in reducing the risk
of cardiovascular diseases. 124 Flavonoids are most widely used as dietary supplements.

1.2 Green Tea
1.2.1 History
Green tea one of the most widely consumed beverages in the world is an aqueous
infusion of dried leaves of “Camellia Sinensis”. The birth place of green tea is in Asia.
Tea plants grow only in warm climates. Although abundant foilage is produced by the tea
plant, only the two leaves and the buds at each young shoot are picked for tea. The type
of tea produced depends on the way in which leaves are processed: green, oolong, black.
Green tea is the least processed tea; it is made by steaming the harvested leaves, rolling
them and then spreading them out to dry until they become crispy (14).
The chemical contents of green tea include; flavonoids such as catechins and
tannins, free amino acids, caffeine, ascorbic acid, saponins, and unsaturated fatty acids. 15,
16

Catechins constitute a major component of green tea, which include Epicatechin (EC),

Epigallocatechin (EGC), Epicatechin gallate (ECG), Epigallocatechin gallate (EGCG).
These compounds constitute 30% of the chemical composition of green tea. 12, 13 The
most active component of green tea is EGCG, which constitutes 9-13% weight of green
tea. It possesses a much greater antioxidant activity than the other catechins, and plays an

7

important role in the prevention of cancer and cardiovascular diseases. 17
A literature Search through Scifinder reveals that there are more than 8000
citations related to chemistry, bioactivity, production and potential health benefits of
green tea. Out of 8000, 4000 references are related to EGCG and other natural products
of green tea. 18

Figure 1.10 : Structure of EGCG

1.2.2 Green tea production and trade
World wide annual production of tea is estimated around 1 million tonnes and 70
percent of it is black tea and remaining is green tea. The world’s major producers of
green tea are China, Japan, Korea, Taiwan, and Indonesia. China accounts for 65 percent
of world production and 85 percents of world exports of green tea, where as Japan
accounts for 20 percent of world production and five percent of world exports. United
States of America and Canada are the major export destinations of green tea. It is also
exported to Germany, United Kingdom, and Saudi Arabia. 11

8

1.2.3 Extraction and purification of green tea.
Various methods are used in extracting and purifying green tea. Most of these
methods are patented. As EGCG is the principal active ingredient of green tea, most of
the methods in extracting green tea are concentrated on extracting the pure EGCG. In
most of the methods, polyphenols of green tea are extracted by solvent extraction, using
different solvents like water, ethanol, diethyl ether, ethyl acetate, acetone etc.
Purification of green tea is performed by using chromatographic techniques. Different
types of columns are used in the separation of polyphenols, like Sephadex LH 20 column,
19

Silica gel column, 20 C-18 attached silica monolith microcolumns, 24 and

Lignocellulose column. 25 Different lengths and particle size of HPLC columns are used
for separation of catechins. 21 Weakly basic anion exchange resins are also used in the
separation of polyphenols. 22 Polyphenols of green tea are also separated by Reverse
phase liquid chromatography, and High speed counter current chromatography. 26, 27
During the purification process the time and temperature at which brewing is performed,
is also considered (higher the brewing time higher the concentration of the catechins in
green tea). 70◦C is recognized as the optimum temperature for achieving the maximum
concentration of polyphenols. 23
EGCG is also synthesized chemically, by the transformation of retero-chalcones into
1, 3-diarylpropene which are then subjected to asymmetric dihydroxylation. The resulting
diarylpropane-1, 2-diols serve as Chiron’s for essentially enantiopure flavan-3-ols. 28-30

9

1.2.4 Bioactivity
Various diseases like cardiovascular diseases and cancer are considered to be caused
by the activity of oxygen radicals; hence they are expected to be prevented by
antioxidative compounds. It is well recognized that tea catechins (+) catechin (+C), (-)epicatechin (-EC), (-) epigallocatechin (-EGC), (-) – epigallocatechin (-EGC), (-) Epigallocatechin gallate show potent antioxidant activity. 73, 74 Epidemiological studies
have shown that the intake of tea catechins decrease the risk of coronary heart disease,
stroke and cancer. 75-77 Hence analysis of radical scavenging activity of the phenolic
compounds present in different types of teas (green tea, oolong tea, black tea) has gained
in importance. Different techniques such as the oxygen electrode method, 69 High
performance liquid chromatography, 70 Electron spin resonance spectrometry, 71 Nuclear
magnetic resonance 72 etc are used to analyze the scavenging activity of catechins on free
radicals.
As mentioned earlier, epigallocatechin gallate (EGCG), the most abundant catechin in
tea catechins, is shown to have the most effective scavenging activity among the tea
catechins. 67 The ortho trihydroxy group in the B ring and the galloyl moiety attached at
3rd position contribute to the strong scavenging activity of Epigallocatechin gallate. 68

10

Figure 1.11: Structure of Catechins (68)

To elucidate the molecular mechanism underlying the radical scavenging and
antioxidant activities of antioxidants, (+)-catechin was reacted with 1, 1- diphenyl-2picrylhydrazyl (DPPH; stable free radical) as a model reaction. The reaction mixture is
analyzed by C13 NMR. Two new carbonyl peaks were detected in the spectra, and the
disappearance of characteristic peaks of the B ring was also observed, suggesting that two
hydroxyl groups in the B- ring are more important in radical scavenging activity among
the 4 phenolic hydroxyl groups of catechin and the B ring was changed to a quinone
structure. Signals ascribable to A and C ring remained unchanged. 72

11

B
A

C

Figure 1.12: Structure of Catechin

Experimental results have shown that the galloyl moiety in epigallocatechin gallate is
more important in radical scavenging activity than the hydroxyl groups on the B ring. 72

Figure 1.13: Galloyl Group

Therefore catechins are useful in the prevention of diseases caused by oxygen
radicals. Consumption of green tea can decrease the cholesterol absorption, can decrease
the body weight by interfering with sympathoadrenal system, inhibit the low density lipid

12

oxidation (LDL), antithrombotic activities and decrease the systolic and diastolic blood
pressure. 79 Catechins may ameliorate the impairments or injuries caused by intracellular
active oxygen (Senile disorders), and might become useful for protecting human from
Alzheimer’s disease. 78
EGCG, the most abundant catechin of green tea catechins, has several health benefits.
However the beneficial effects of EGCG on human diseases are inconclusive, therefore
epidemiological studies on protective action of green tea and EGCG yet to be explored

1.3 Crystal engineering
1.3.1 Introduction
Crystal engineering “the design of solids” 62 is target oriented and property directed
synthesis of molecular crystals. 80 Traditionally, crystal engineering focuses on the
relationship between the structure and properties of solids. Currently this concept is
expanded into diverse areas such as material chemistry, supramolecular chemistry,
molecular recognition and biology. 81
The term “Crystal engineering” was introduced by Pepinsky (1955) in the context of
crystallization of organic ions with metal complexes. 63 Schmidt applied the concept of
crystal engineering in the context of solid state photodimerisation reactions. 64 Modern
Crystal engineering can be described as an interdisciplinary subject, owing to its
implications for organic, inorganic, metal organic, theoretical and materials chemistry. 65
A more useful definition for crystal engineering is provided by Desiraju, who illustrates

13

crystal engineering as a field with broader discipline “designing crystals with desired
properties”.
Definition
“Crystal engineering is the understanding of intermolecular interactions in the context of
crystal packing and in the utilization of such understanding in the design of new solids
with desired physical and chemical properties”. 62
Gautam Desiraju.
The concept of crystal engineering has been successfully exploited in the synthesis of
porous solids 82 and ion exchange materials. 83 Crystal engineering strategies are applied
in the design of pharmaceuticals, 38 photographic materials, 84 and in novel optical,
electronic and magnetic materials.
1.3.2 Pharmaceutical Crystal Forms
The majority of the drug substances are solid dosage forms, most of which contain
active ingredient in a crystalline state. The inherent stability of crystalline materials and
the well established impact of crystallization process on purification and isolation have
made the chemists and the engineers to deliver the pharmaceutically active compounds in
crystalline form. 31 The physical properties of the crystal such as purity, size and shape
are determined by the operating conditions of crystallization process, in turn these
properties determine the efficiency of the operations filtration, drying, formulating and
also product effectiveness such as bioavailability and shelf-life. Drug dissolution and
toxicity are affected by solid state phase and purity of the product, this leads to batch to

14

batch uniformity and consistency. Therefore, improved control of crystallization
processes can achieve better crystal product quality, shorter process time and elimination
of compromised batches. 32
Pharmaceutical crystals may be chiral or achiral and they may exist in different
forms, salts, solvate or hydrate and polymorphs. The existence of a crystal in different
crystalline phases results in polymorphs. 40 Solvates are “Molecular complexes that have
incorporated the crystallizing solvent molecule in their crystal lattice”. 41 When a crystal
lattice incorporates water, it is designated as a hydrate. Approximately one third of
pharmaceutical substances are capable of forming crystalline hydrates. 42 Solvates and
hydrates demonstrate different solubilities and dissolution rates when compared to their
unsolvated counter parts. 43 The stability of the hydrates and solvates at different
temperatures and different vapor pressure, differ from their unsolvated forms. 44 These
differences can influence the stability of the pharmaceutical substances under different
storage conditions.
The physical and chemical properties of a crystal depend upon the arrangement of the
molecules in it and the physiochemical properties of the solid drug can affect its
performance. Thus a study of the crystalline state can lead to an understanding of the
drug properties which are important for preformulation and formulation. Different crystal
packing changes the periodicity of the molecules which may in turn change physical
properties of various crystal forms. 40, 45 Therefore, different solid forms can show
different physical and chemical properties. Pharmaceutical drugs with different solid
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forms can lead to phase transformations during processing and formulation, such as in
theophylline, 46 carbamazepine, 47 Phenobarbital, 48 lactose 49 etc. The stability and
bioavailability of the drug are affected by these phase changes. 50 Therefore, an
understanding in relationship between the solid state properties and crystal structures can
be utilized for optimizing formulation strategies and in designing suitable stability
protocols. 51, 52 Different solid forms of excipients, used in pharmaceutical formulations,
can also affect the final physical form of a tablet. 53, 54
Opposite enantiomers of chiral drugs, show different pharmacological, toxilogical,
pharmacodynamic and pharmacokinetic properties. This is due to the molecular
environment, in which these solids exist. 55, 56 The presence of ions in pharmaceutical
salts influences the physiochemical properties of the crystals, like dissolution rate,
stability, solubility and hygroscopicity. 57
The structure of the crystal also affects mechanical properties, for example the
intermolecular hydrogen bonds in theophylline monohydrate results in higher mechanical
strength and less brittle than the anhydrous form of theophylline. 58 Similarly, the
presence of water molecules in the monohydrate of 4-hydroxy benzoic acid facilitates its
plastic deformation. 59 Therefore, it is possible to predict the mechanical properties from
its crystal structure.
Different crystal forms of drug substances with different physiochemical properties
can also affect scale up and transfer from laboratory quantities and procedure through
pilot plant and full production. 60 The characterization of crystal forms plays a major role
in quality control and regulatory processes. 61
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Physiochemical properties including mechanical properties of crystalline drug are
determined by its molecular arrangement, packing, conformation and intramolecular
interactions in its lattice. These physiochemical properties affect the pharmaceutical
properties of the drug product. In order to predict the properties of pharmaceutical
crystals a thorough understanding of the underlying crystal structure is desirable. 40
1.3.3

Patent Relevance of Crystal Forms

“Patents are a mechanism for promoting research for society’s benefit: the right to
exclude others from practicing a patented invention affords an economic incentive to the
inventor, while the limited term of the exclusionary right ultimately delivers the invention
into the public domain”. 87
Andrew V. Trask
Patent can be defined as “A license conferring the sole right to manufacture, sell, or
deal in a product or commodity; (now) spec. a license from a government conferring for a
set period the sole right to make, use, or sell some process or invention”.
Oxford English Dictionary
Criteria for obtaining a patent:
A product or process must have novelty (not part of the “state of the art”), utility (must
serve some worthwhile practical use), and must not be obvious (competent but without
imagination). A product must be of human ingenuity, and should contain an enabling
description.
M.J. Zaworotko
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Newness of the drug product can be attributed not only for a new bioactive chemical
form, but also for a different solid state form (polymorphic, amorphous or chiral),
combination with other solids (carriers, coating, excipients), and different delivery
method or even for a different proportion of the drug in this combination 85 are patented.
Crystallization methods for a particular solid state form, new drugs, related
manufacturing, and formulation aspects are protected by patents.
Examples
•

Co-crystallization process (patent number; WO0053283, Authors; Reuter Karl,
Reuter Chemische Apparatebau)

•

A process for preparation of urea complexes of vitamin E and its esters (Patent
number; IN182620, Authors; Bajaj Vikas; Madan Anil Kumar )

•

High-throughput formation, identification, and analysis of diverse solid-forms
(patent number; 20030162226, Authors; Cima, Michael J.; Levinson, Douglas;
Lemmo, Anthony V.; Galakatos, Nicholas; Putnam, David A.;)

•

Novel Conazole crystalline forms and related processes, pharmaceutical
compositions and methods (patent number; WO03101392, Remenar Julius;
MacPhee Michael; Peterson Matthew Lynn; Morissette Sherry L; Almarsson
Orn)

Crystal forms of the chemical substances are patented on their powder X-ray diffraction
pattern, because the powder pattern of a crystalline form is recognized as a finger print of
it. Chemical substances can exist in more than one crystal form; this phenomenon is
referred to as polymorphism. As different polymorphs of the same drug can exhibit
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widely different solubility and bioavailability properties, polymorphism became an
immediate concern for pharmaceutical industries during patent filing. A polymorph of a
drug can be entitled to a different patent protection, as it has a different legal entity. For
example, the two polymorphs of Zantac (ranitidine hydrochloride) are patented by GlaxoWellcome.
Ranitidine hydrochloride 86

Figure 1.14: Form I

Figure 1.15: Form II

Powder pattern for polymorphs of ranitidine

Figure 1.16: Powder X-ray diffraction of form I and II
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As methods in generating the new patents guarantee the future financial security of the
company, a complete screening and characterization of single crystal forms and
development of corresponding crystallization techniques should be carried out as early as
possible.
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2. CSD STATISTICS
2.1 Cambridge Structural Database (CSD)

Cambridge Crystallographic Data Centre (CCDC) was established by Olga Kennard at
Cambridge University in 1965. Cambridge structural data base is the principal product of
the CCDC. 33 The CSD comprises software for database access, structure visualization,
data analysis, and structural knowledge bases derived from the scientist’s world wide. It
records X-ray and neutron diffraction data of organic and metal organic compounds. It
also records bibliographic, chemical and crystallographic information of these
compounds. Crystallographic information includes single crystal studies and powder
diffraction studies. Crystal structure data arising from the publications in the open
literature and from private communications are also included in CSD.
CSD software includes ConQuest (search program), Mercury (visualiser), Vista
(statistical analysis), and Prequest (database creation) (33).
2.2 Supramolecular chemistry
“Supramolecular chemistry” 90which is also known as “chemistry beyond the
molecule” 91is based on the selective recognition of molecules which interact via non
covalent forces to form well organized assemblies. During the 1960’s and 1970’s much
of the supramolecular chemistry research, involved in host guest systems 91 for selective
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binding of small alkali metal cations by macrocyclic receptors. The fascination for
molecular recognition phenomenon inspired chemists in further exploration of
supramolecular systems in the context of weak intermolecular interactions such as
hydrogen bonds. 92-98
2.3 Supramolecular synthons
The term synthon was introduced by Corey in 1967 (99). Corey defined synthon as;
“ ……. Structural units within the molecules can be formed or assembled by known or
conceivable synthetic operations”. The term synthon is traditionally used in representing
the key structural features in target molecule in organic synthesis.
Crystal engineering has emerged around the idea of establishing and later utilizing the
intermolecular interactions to govern the crystal packing with reasonable predictability.
In this respect the term supramolecular synthon was introduced by Desiraju in 1995. 34 It
is defined as “a structural unit within the supermolecule which can be formed and/or
assembled by known or conceivable intermolecular interactions”. Supramolecular
synthons are also called as motifs 100 or patterns. 101 They can also be regarded as regions
within a crystal structure where the recognition between constituent functional groups
occurs. 102 Supramolecular synthons can be separated in to two distinct categories:
Supramolecular homosynthon; which results from interaction of identical selfcomplementary functionalities 35 and supramolecular heterosynthon which results from
interaction of different but complementary functionalities35. Examples of supramolecular
homosynthons include carboxylic acid and amide dimmers, 103,104 while supramolecular
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heterosynthon include acid-pyridine, 35acid –amide 105-108and hydroxyl- pyridine.109-111
Figure 2.1 represents the acid-acid dimmer (homosynthon) and acid – pyridine
(heterosynthon).

Figure 2.1 Examples of supramolecular homosynthon (left) and supramolecular heterosynthon
(right)

Supramolecular homosynthons tend to be observed in single component crystals, but
their existence can also be observed in multiple component crystals in which each
component has at least one identical functional group. Furthermore when multiple
functional groups are present the formation of a supramolecular heterosynthon is
possible. Supramolecular heterosynthon can exist between the functional groups located
on two different molecules with same chemical make up or on the two different
molecules with different chemical make up. Interpretation of existing crystal structures
with complete knowledge on interplay between supramolecular synthons would help in
designing new multicomponent crystals.
2.4 CSD Statistics for Polyphenols
The polyphenolic nature of the flavonoids provoked an interest to conduct a survey on
intermolecular interactions of phenols and polyphenols in the CSD. Phenols and
polyphenols are evaluated by considering the following constraints, no ions, only
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organics, R factor: <=0.075, structures containing 3D coordinates. As EGCG contains
ether, ester and alcohol groups, while the two known solvates of it contain acetonitrile
and nitrobenzene, studies are conducted considering these functional groups.
There are 6,032 phenols in CSD as of May 2007. Out of 6,032 phenols 1,005 are
polyphenols.

OH
OH

Figure 2.2: Structure of polyphenol considered in the CSD search

H
O

H

O
R

O
O

H

O

I

H

O

R

R

R

O

II

III

Figure 2.3: Synthon I; OH---OH, Synthon II OH---CO, Synthon IIIOH----O(ether) interactions,
(R:C6H5OH)
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In CSD analysis, the frequency of occurrence of supramolecular synthons hydroxyl to
hydroxyl (synthon I), hydroxyl to carbonyl of ester (synthon II) and hydroxyl to ether
(synthon III) in phenols and polyphenols is evaluated. In order to determine appropriate
distance ranges, within which homo and heterosynthons exist, distance histograms were
generated. Based on visual inspection of the resulting interactions in the crystal structures
included in the histograms, the lower and higher cut offs for hydrogen bond distances
were determined. The histograms (Fig 0.2) revealed that hydroxyl to hydroxyl synthon
(I) occurs within a distance range of 2.6-3.0 Å. Supramolecular synthons II (hydroxyl to
carbonyl of an ester) and III (hydroxyl to ether) exist within a range of 2.56-2.94 Å and
2.5-3.0 Å respectively.

Figure 2.4:Histograms of contacts for supramolecular synthons I (OH---OH), II (OH---CO) and
(OH----O) III
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Figure 2.5: Synthon IV represents OH---CN and Synthon V represents OH---NO interaction

Similarly hydroxyl to cyano group Synthon (synthon IV as represented in figure 2.5)
and hydroxyl to nitro group synthon (synthon V as represented in figure 2.5) were
evaluated. Histograms revealed the distance ranges within which these synthons occur are
2.7- 3.2 Å and 2.78 - 3.06 Å respectively.

Figure 2.6 : Histograms of contacts for supramolecular synthons IV
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Phenols

Polyphenols

836 hits/6,032
14.8%

385 hits/1,005
38.3%

Synthon I
(OH---OH)

Table 2.1: Frequency of occurrence of synthon I in phenols and polyphenols

Phenols

Polyphenols

Phenol +
Ester

OH--CO
(ester)
2.562.94Å

Phenol+
ether

OH---O
(ether)
2.5-3.0 Å

Phenol
+ Cyano
group

OH---CN
2.7 -3.2Å

Phenol +
Nitro
group

OH---NO
2.783.06Å

799
hits/6,032
phenols

225
hits/799

2,074
hits/6,032

199 hits/
2,074

187 hits/
6,032

74 hits/
187

370 hits/
6,032

83 hits/
370

191 hits/
1,005
polyphenols

81
hits/191

281
hits/1,005

50
hits/281

38 hits/
1,005

21
hits/38

31 hits/
1,005

11 hits/31

Table 2.2: Frequency of occurrence of synthons from II to V in phenols and polyphenols

Table 2.2 represents the frequency of occurrence for synthons II to V in the presence
of the respective functional groups with phenols and polyphenols. Though the presence
of ethers with phenols and polyphenols is high in comparison with other functional
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groups, the occurrence of synthon III is relatively lower compared to the other synthons.
Supramolecular
synthons

D----A (Å)

Mean (Å)

OH----OH

2.6 -3.0 Å

2.80

OH---CO (ester)

2.56-2.94

2.771

OH---O (ether)

2.5-3.0

2.805

OH----CN (cyano)

2.7-3.2

2.873

Table 2.2.3: Distance ranges within which different synthons exists

This analysis has revealed that the frequency of occurrence of hydroxyl to hydroxyl
synthon (synthon I) is higher in phenols (14.8%) and polyphenols (38.3%), when
compared to other synthons (II, III, IV and V). The prevalence of the specific
supramolecular synthons in these crystal structures would provide a valuable insight for
crystal engineering strategies in generation of new multicomponent materials comprised
of polyphenols.
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3. EXPERIMENTAL DATA

Some solvents were obtained from Sigma Aldrich. Distillation of few solvents was
performed in the lab itself, such as methanol, ethanol, dichloromethane, chloroform.
Distilled water is used. EGCG was provided by Dr. Roland Shytle.

3.1 Infrared Spectroscopy (IR)
A Nicolet Avtar 320 Fourier transform Infrared spectrometer was used for collecting
the IR spectra of the samples (sample concentration 2mg). The spectra were measured
over the range of 4000 – 400cm-1. Data were analyzed by using EZ Omnic software.

3.2 Differential Scanning Calorimetry (DSC)
Thermal analysis of the samples was performed on TA instrument DSC 2920
equipped with liquid nitrogen cooling. The samples of crystals (2mg-7mg) were placed in
aluminum pans, and were scanned at 10° C/min in the range 25° - 350° C under a dry
nitrogen atmosphere (flow rate 70ml/min). The data were managed by TA universal
analysis.

3.3 Powder X-ray Diffraction (PXRD)
PXRD patterns were collected on Bruker AXS D 8 powder diffractometer with a Cu
Kα radiation (1.540 56Å). The tube voltage and amperage were set at 50kV and 40mA,
respectively. Each sample was scanned between 3 and 40° in 2θ with a step size of 0.02°.
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The experimental PXRD patterns and calculated PXRD patterns from single crystal
structures were compared to confirm the composition of materials.

3.4 Single Crystal X-Ray Crystallography
Crystals of forms II, III and IV were examined under a microscope and suitable single
crystals were selected for X-ray analysis. Data were collected on a Bruker–AXS SMART
APEX CCD diffractometer with monochromatized Mo Kα radiation (λ = 0.71073 Å)
connected to KRYO-FLEX low temperature device. Data were collected at 100 K.
Lattice parameters were determined from least square analysis, and reflection data were
integrated using the program SAINT. Lorentz and polarization corrections were applied
for diffracted reflections. In addition, the data was corrected for absorption using
SADABS. Structures were solved by direct methods and refined by full matrix least
squares based on F2 using SHELXTL. All non-hydrogen atoms were refined with
anisotropic displacement parameters. All H-atoms bonded to carbon atoms, except
methyl groups, were placed geometrically and refined with an isotropic displacement
parameter fixed at 1.2 times Uq of the atoms to which they were attached. N or O bonded
protons, as well as H-atoms of methyl groups, were located from Fourier difference map
and refined isotropically based upon the corresponding N, O or C atom (U(H)=1.5Uq(N,
O)).
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3.5 Form I
90% pure EGCG provided by Dr.Roland Douglas Shytle is considered as form I. Up
to the date the reported form of egcg in literature is form I. This is confirmed by
PXRD. 88

3.5.1. Physical properties
Melt-Temp: 220° C, Soluble in ethanol, methanol, ethyl acetate, acetonitrile, acetic
acid, formic acid. It is insoluble in chloroform, cyclohexane, toluene, and hexane. Egcg is
sensitive to light, so it is stored at temp 2°- 8°C.

3.5.2 IR of Form I
The IR of form I match with the IR found in literature. 89
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Figure 3.1: IR of Form I
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3.5.3 DSC of Form I
Phase transitions are observed at 126.43° C and 227.71°C. DSC matches with the
DSC in the literature. 88

Figure 3.2: DSC of Form I

Figure 3.3: DSC of Form I from Literature
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3.5.4 Powder X-ray Diffraction of EGCG form I
PXRD of 90% pure EGCG matches with PXRD of EGCG obtained in the literature.
Major peaks; 90% egcg (literature) 5.32 (5.72), 8.63 (8.63), 10.48 (10.4), 12.24 (11.998),
17.14 (16.993), 20.86 (20.656), 24.541 (24.66), 29.68 (29.653).

Figure 3.4: PXRD of Form I

Figure 3.5: PXRD of Form I from literature
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3.6 Form II
3.6.1 Synthesis
65mg of 90% pure epigallocatechin gallate (0.141 moles) dissolved in 1ml of
acetonitrile (99% pure) is layered on 2.5 ml of dichloromethane and allowed to stand in
refrigerator. After 72 hours colorless platelet crystals (Form II) were observed. An
increase of 3-fold and 5-fold in contents has shown same results. Form II was also
crystallized from acetonitrile and chloroform.

3.6.2 Physical properties
Melt- Temp: 235-238°C. Solubility properties are observed to be similar to that of
Form I. Crystals are stable up to four days at temperature 2° to 8° C. Upon heating at
120° C for twenty minutes, solvent is evaporated, and Form II is converted to Form IV.

3.6.3 IR of Form II
IR of form II shows O-H stretch 3323.8 cm-1, C=O stretch at 1605 cm-1, and
aromatic carbon stretch at 742.4 cm-1.
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Figure 3.6: IR of Form II

34

987.29

742.49

1315.48
1242.12
1208.03
1140.11

88

824.22

89

1033.83

90

1097.22

1449.94
1381.08

91

1605.01

%T

92

1000

3.6.4 DSC of Form II
Phase transitions are observed at 101.43° C and 252.71°C.

Figure 3.7: DSC of Form II

3.6.5 TGA of Form II
Below 100° C 16.68 % weight loss is observed. 20.20 % weight loss is observed
between 230° C.

Figure 3.8: TGA of Form II
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3.6.6 Powder X-ray Diffraction of form II
The experimental PXRD matches with the calculated PXRD as shown in fig 3.11.
Major peaks, experimental (calculated): 7.12 (7.12), 7.8 (7.92), 8.46 (8.56), 13.04 (13.3),
15.24 (15.28), 23.54 (23.86), 25.92 (25.44).

Figure 3.9: Experimental PXRD of Form II

Figure 3.10: Calculated PXD of Form II
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Figure 3.11: Calculated Vs Experimental PXRD of Form II

3.6.7 Picture of Single crystal

Figure 3.12: Single crystal of Form II
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3.6.8. Single Crystal X-ray Crystallography Data
Molecular formula: C24 H21 N O11; Formula weight: 499.42; Crystal system:
Monoclinic; Space group: C2; Unit cell dimensions: a = 22.876(3) Å, b = 14.9054(17) Å;
c = 15.8886(18) Å, α =90◦; β =102.688(2)◦;γ = 90°; Volume: 5285.4(10)Å3; Z=8;
Temperature:100(2) K; Density (calculated): 1.433 Mg/m3 ; λ(Mo-Kα): 0.71073 Å ;
Reflections measured: 12985; Independent reflections: 10165 [R(int) = 0.0277]; Final R
indices [I>2sigma(I)]: R1 = 0.0831, wR2 = 0.1993; R indices (all data): R1 = 0.1013,
wR2 = 0.2144

3.7 Form III
3.7.1 Synthesis
In a typical reaction, a reaction tube with 6ml of dichloromethane is taken, and 1ml of
nitrobenzene is layered on it. 200mgs (0.436mmoles) of 90% pure EGCG dissolved in
2.5ml of acetonitrile is layered on nitrobenzene. Reaction test tube is left on refrigerator,
after 24 hours yellow needle like crystals were observed

3.7.2 Physical properties
Melt Temp: 235 °-238°; Solubility properties are similar to that of Form I. Form III
crystal are more stable compared to Form II crystals at temp 2°- 8° C. Upon heating to
120° C for twenty five minutes, Form III converts to Form IV.
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3.7.3 IR of Form III
3272.3 cm-1 (O-H stretch), 1681.33 (N-O stretch) are observed.
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Figure 3.13: IR of form III

3.7.4 DSC of Form III
Phase transitions are observed at 140.10°C, 169.26° C, and 253.52°C.

Figure 3.14: DSC of Form III
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3.7.5 TGA of Form III
11.98 % of weight loss is observed at 131° C, 25.31 % of weight loss is observed at
211.36° C is observed.

Figure 3.15: TGA of Form III

3.7.6 Powder X-ray Diffraction of form III
The experimental PXRD matches with the calculated PXRD as shown in fig
3.18.Major peaks, Experimental (calculated): 13.4 (13.4), 15.4 (15.4), 19.4 (19.44), 24.3
(24.4), 27.8 (27.65), 28.5 (28.5), 31.3 (31.3), and 37.6 (37.5)

Figure 3.16: Experimental PXRD of Form III
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Figure 3.17: Calculated PXRD of Form III

Figure 3.18: Calculated Vs Experimental PXRD of Form III
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3.7.7. Picture of single crystal

Figure 3.19: Single crystal of Form III

3.7.8. Single Crystal X-ray Crystallography Data
Molecular formula: C28 H25 N O14; Formula weight: 599.49; Crystal system:
Orthorhombic; Space group: P2(1)2(1)2(1); Unit cell dimensions: a = 13.2070(14) Å, b =
13.2134(14) Å; c = 14.5781(16) Å, α = β = γ = 90°; Volume: 2544.0(5) Å3;
Z=4;Temperature:100(2) K; Density (calculated): 1.565 Mg/m3 ; λ(Mo-Kα): 0.71073 Å ;
Reflections measured: 11442; Independent reflections: 4964 [R(int) = 0.0608]; Final R
indices [I>2sigma(I)]: R1 = 0.0605, wR2 = 0.1126; R indices (all data): R1 = 0.0787,
wR2 = 0.120
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3.8. Form IV
3.8.1 Synthesis
Form IV is obtained by heating form II and III at 120° for 20-25 minutes. Form IV
crystals: EGCG (45mg, .098mmoles of form IV powder obtained by heating form III at
120◦ C for 25 minutes) is dissolved in 1ml of acetonitrile (99%pure, Aldrich). The
solution is layered on 2.5ml dichloromethane (distilled and stored over molecular sieve)
and seeded with form IV crystals obtained by heating form III (at 120◦ C for 25 minutes)
and was allowed to stand in refrigerator. After one week colorless needle like crystals
were observed.

3.8.2. Physical Properties
Melt-Temp: 232°-235°. Solubility properties are similar to that of form I.

3.8.3. IR of Form IV
3466.81cm-1 (O-H stretch), 1606.19 (C=O) stretch are observed.

Figure 3.20: IR of Form IV
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3.8.4 DSC form IV
Phase transition is observed at 250.08 °C

Figure 3.21: DSC of Form IV

3.8.5 TGA form IV
30.02 % of weight loss is observed at 251.78° C.

Figure 2.22: TGA of Form IV
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3.8.6 Powder X-ray Diffraction of form IV
The experimental PXRD matches with the calculated PXRD as shown in fig 3.24.
Major peaks (experimental): 13.9 (13.84), 17.2 (17.12), 21.2 (21.16), 23.6 (23.64), 26.5
(26.6), 29.0 (29.16), and 31.5 (31.7).

Figure 3.22: Experimental PXRD of Form IV

Figure 3.23: Calculated PXRD of Form IV
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Figure 3.24: Calculated Vs experimental PXRD of Form IV

3.8.7 Picture of Single Crystal

Figure 3.25: Single crystal of Form IV
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3.8.8 Single Crystal X-ray Crystallography Data
Molecular formula: C22H18O11; Formula weight:458.36; Crystal system: Monoclinic;
Space group: P2(1); Unit cell dimensions: a = 13.006(10) Å, b = 5.686(4)Å; c =
13.089(10) Å, α = 90°;β =107.062(11)° ;γ = 90°; Volume: 925.4(12)Å3; Z=2;
Temperature: 100(2) K; Density (calculated): 1.645 Mg/m3 ; λ(Mo-Kα): 0.71073 Å ;
Reflections measured: 2623; Independent reflections: 2550 [R(int) = 0.0312]; Final R
indices [I>2sigma(I)]: R1= 0.0641, wR2 == 0.1494; R indices (all data): R1 =0.0800,
wR2 = 0.1674
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4. RESULTS AND DISCUSSION

4.1

Structure Description

EGCG structure; EGCG consists of 4 rings (A, B, C, D) with 8 hydroxyl groups, as
shown in Fig4.1. In all forms of EGCG the A and C ring lie in one plane while rings B
and D lie in different planes with different dihedral angles. EGCG makes full use of all
hydroxyl groups to form different synthons such as hydroxyl to hydroxyl, hydroxyl to
ether, hydroxyl to carbonyl of ester, hydroxyl to cyano and hydroxyl to nitro.

B
A

C

D

Figure 4.1: Structure of EGCG

4.1.1 Form II
The crystal structure of form II was obtained from Single crystal X-ray diffraction as
described in the experimental section. Form II solvate of acetonitrile, crystallizes in the
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monoclinic C2 space group with two egcg and two acetonitrile molecules and some
disordered solvent molecules in asymmetric unit. Analysis of the structure of form II
indicates the presence of four type’s synthons. They are hydroxyl to hydroxyl (OH--OH), hydroxyl to ether (OH---O), hydroxyl to cyano group (OH---CN), and hydroxyl to
carbonyl of ester (OH---CO) synthons.
The OH---OH hydrogen bond exists in between, the two hydroxyl groups of the D
ring of molecule I and one hydroxyl group of B ring of molecule II. The OH---OH
hydrogen bond is observed between hydroxyl group on the B ring of molecule I and two
hydroxyl groups of D ring of molecule II and also in between the hydroxyl group on the
A ring of molecule I and the hydroxyl group of A ring on molecule III. The hydrogen
bond distances in synthon OH----OH are 2.999Å, 2.733Å, 2.753Å, 2.838Å, and2.603Å.
The distances are consistent with the CSD analysis (2.6 – 3.0Å).

Molecule
II

Molecule
I

Molecule
III

Figure 4.2: Representation of OH----OH synthon in Form II
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The OH---O (ether) hydrogen bond exists between the oxygen of the C ring and the
hydroxyl of the D ring. The hydrogen bond distance in OH---O synthon is 3.026Å which
is consistent with the CSD analysis (2.5-3.0Å).

Figure 4.3: Representation of OH---O synthon in form II

The OH---CO (ester) hydrogen bond exists between the ester carbonyl of molecule I
and the hydroxyl on the D ring of molecule II and also with the two hydroxyl groups on
the B ring of molecule II. The hydrogen bond distances in synthon OH---CO are 2.847Å,
2.924Å, and 2.680Å. The distances are consistent with the CSD analysis (2.56-2.94Å).
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Molecule
II

Molecule
I

Molecule III

Figure 4.4: Representation of OH---CO synthon in form II

The OH---CN hydrogen bond exists between the hydroxyl group on the B ring and
cyano group of acetonitrile molecule. The hydrogen bond distance in the synthon OH--CN is 2.898Å which is consistent with the CSD analysis (2.7-3.2 Å).

Figure 4.5: Representation of OH---CN synthon in form II
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Acetonitrile molecules are embedded in between egcg molecules and sustained by
hydrogen bonding.

Figure 4.6: Solvent entrapment in form II

Unit cell packing of form II includes 8 egcg molecules, 8 acetonitrile molecules, and
disordered solvent molecules.

Figure 4.7: Unit cell packing of form II
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4.1.2 Form III
Form III solvate of nitrobenzene crystallizes in orthorhombic P2 (1) space group with
one egcg molecule, one nitrobenzene and one water molecule in asymmetric unit.
Analysis of form III crystal indicated the presence of four types of synthons. They are
hydroxyl to hydroxyl (OH---OH), hydroxyl to carbonyl of ester (OH---CO), hydroxyl to
nitro (OH---NO) and hydroxyl to oxygen in water (OH---O).
Figure 4.7 represents the OH----OH interactions of molecule I and molecules II, III,
IV and V. One of the hydroxyl group on the A ring of molecule I and hydroxyl groups on
the B and D ring of molecule V form hydrogen bond. The other hydroxyl group of A ring
in molecule I forms hydrogen bond with the hydroxyl group on the B ring of molecule II.
The hydroxyl group on the B ring (of molecule I) forms hydrogen bond with hydroxyl
group on the B ring of molecule III. The two hydroxyl groups on D ring (molecule I)
form hydrogen bond with hydroxyl group on the A ring of molecule IV and also with
hydroxyl group on the B ring. The hydrogen bond distances in the synthon OH----OH are
2.910Å, 2.827Å, 2.831Å, 2.827Å, 2.910Å, and 2.982Å. The distances are consistent with
the CSD analysis (2.6-3.0Å).
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Molecule IV

Molecule II

Molecule III
Molecule I

Molecule V

Figure 4.8: Representation of OH----OH synthon in Form III

The OH---CO (ester) hydrogen bond exists between the carbonyl of the EGCG molecule
and the hydroxyl group on the A ring of another EGCG molecule. The hydrogen bond
distances in OH—CO synthon is 2.671Å which is consistent with the CSD analysis
(2.56-2.94Å).

Figure 4.9: Representation of OH---CO synthon in Form III
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The OH---NO hydrogen bond is observed between the hydroxyl group of B ring and
nitro group of nitrobenzene. Hydrogen bond distance in the synthon OH---NO is 2.773Å
which is consistent with the CSD analysis (2.7- 3.2Å).

Figure 4.10: Representation of Synthon OH---NO in Form III

The OH—O hydrogen bond is observed between the hydroxyl groups on B ring and
oxygen of water molecule. The hydrogen bond distances in the synthon OH---O (water) are
2.837Å, 2.957Å, and 2.610Å.

Figure 4.11: Representation of Synthon OH---O in Form III
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Nitrobenzene molecule is sandwiched between two egcg molecules and sustained by
hydrogen bond.

Figure 4.12: Solvent entrapment in form III

Unit cell of form III contain 4 egcg molecules, 4 nitrobenzene molecules and 4 water
molecules

Figure 4.13: Unit cell packing of Form III
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4.1.3 Form IV
Form IV of egcg crystallizes in monoclinic P2 (1) space group with one egcg
molecule in asymmetric unit. Form IV exhibits three types of synthons. They are OH--OH, OH---CO (ester), and OH----O (ether).

Figure 4.14: Representation of Form IV structure

The OH---OH hydrogen bond in form IV exists between the hydroxyl groups on A
ring of molecule I and hydroxyl group on B and D rings of molecules VI, and IV
respectively. The hydroxyl groups on the D ring of molecule I exhibits OH---OH
hydrogen bond with hydroxyl group on the A and B rings of molecules IV and III
respectively. The hydroxyl group on the B ring of molecule I exhibits the OH---OH
hydrogen bond with hydroxyl group on the A ring of molecule II. The hydrogen bond
distances in the synthon OH---OH are 2.801 Å, 2.697Å, 2.696Å, and 2.960Å. The
distances are consistent with the CSD analysis (2.6 -3.0 Å).
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Molecule II
Molecule I
Molecule VI

Molecule V
Molecule III
Molecule IV

Figure 4.15: Representation of OH---OH synthon in Form IV

The OH—O (ether) hydrogen bond exists between the hydroxyl group of the B ring
and the oxygen in the C ring of another molecule. The hydrogen bond distance of synthon
OH---O is 2.875Å which is consistent with the CSD analysis (2.5-3.0Å).

Figure 4.16: Representation of OH—O synthon in Form IV
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The OH---CO (ester) interaction is observed between the carbonyl of molecule I and the
hydroxyl groups on the B and D rings of molecules II and III respectively. The hydrogen
bond distances in the synthon OH----CO are 2.813Å, 2.839Å, and 2.879Å. The distances
are consistent with the CSD analysis (2.56-2.94Å).
Molecule I

Molecule II

Molecule III

Figure 4.17: Representation of OH—CO synthon in FormIV

59

Unit cell of form IV contain two egcg molecules

Figure 4.18: Unit cell packing of Form IV

4.2 Conformational analysis
Conformational flexibility in the EGCG molecule was previously analyzed by proton
NMR. 115 It includes the orientation of the linkage between B, D and C ring owing to the
puckering of C ring. The conformational changes in C ring with respect to the B and D
rings, gives rise to 4 conformers (A, B, C, and D).

Conformer A

Conformer B

R1= Pseudoequitorial

R1 = Pseudo axial

R2 = Pseudo axial

R2= Pseudoequitorial

Conformer C

Conformer D

R1= Pseudoequitorial

R1 = Pseudo axial

R2= Pseudoequitorial

R2 = Pseudo axial
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Figure 4.19: Representation of different conformations of EGCG (116)

The pseudoequitorial and pseudoaxial positions of the B and D rings with respect to
the C ring in forms II, III, and IV suggest that they exist as conformer A. The puckering
of the C ring generates the pseudoequitorial and pseudoaxial positions of rings B and D.

C2

C1

Form II

C2

C1 C2

Form III

C1

Form IV

The two chiral centers (C1 and C2) on C ring exists in S, S, for form II and R, R for
forms III, IV respectively.
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4.3 Discussion
Although flavonoids are abundant and commercially available they are difficult to
purify and crystallize. In this respect developing new crystal forms of EGCG was
challenging. Different crystallization techniques were explored in crystallizing EGCG,
such as solvent evaporation, vapor diffusion, slow cooling, and solvent layering. Solvents
used in these techniques were ethanol, methanol, toluene, cyclohexane, hexane, 1, 4dioxane, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane,
acetonitrile, nitrobenzene, benzene, and water. Solvent layering technique was found to
be the most successful technique in crystallizing EGCG. As mentioned in chapter 3, two
solvates and a new form of EGCG were obtained by solvent layering technique.
Liquid chromatography- Mass spectrometry (LC-MS) was used to evaluate the
purity of crystals of the two solvates and the new form of EGCG. The LC-MS results
have revealed the presence of impurities. An impurity with mass/charge ratio 443
(retention time 13 minutes), was observed in all three forms.

Figure 4.20: LC-MS analysis of 90% pure EGCG
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Figure 4.21: LC-MS analysis of Form II

Figure 4.22: LC-MS analysis of Form III
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Figure 4.23: LC-MS analysis of of Form IV

Figures 4.20-4.23 represents the LC-MS analysis of all four forms of EGCG.LC-MS
Data: Retention time; EGCG: 7.609 (Mol.wt of EGCG: 458.4), Impurity: 13.039
minutes.

Retention Bulk

Form II

Form III

Form IV

459 (M+1)

459 (M+1)

443 (M+1)

443 (M+1)

481 (M+38) 506 (M+63)

481 (M+38)

523 (M+80)

506 (M+63)

506 (M+63)

time
7.609

459 (M+1) 459 (M+1)
481 (M+23)

13.039

443(M+1)

443 (M+1)

Table 4.1 : Representing the components eluted at different retention times
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Here in table 4.1, bulk represents the 90% pure EGCG. LC-MS results have revealed
that from all four forms, EGCG was eluted after 7minutes and the impurities after
13minutes. Identities of impurities were not determined.
Though crystallization techniques could not produce 100% pure EGCG, a careful
analysis of the existing supramolecular synthons in the new crystal forms can provide an
educated guess to choose other molecule with complementary components when
designing co-crystals. Considering the CSD analysis (chapter 2), a complete knowledge
on interplay between the supramolecular synthons (OH—OH, OH---CO, OH---O, OH--CN, OH---O) would help to develop a strategy in choosing the co-crystal formers.

65

5. CONCLUSION
In summary the study presented herein involves the synthesis of different crystal
forms of EGCG with limited CSD analysis on supramolecular synthons that exist in these
crystal forms. In crystallizing EGCG the technique known as solvent layering was found
to be the most successful technique. Two solvates, with acetonitrile and nitrobenzene,
and one new form of EGCG is reported. A total of five types of synthons exist in the
crystal forms of EGCG. Synthons I (OH---OH), and II (OH---CO (ester)) exist in all three
forms (II, III and IV). The absence of synthon III (OH---O (ether)) in form III suggests
that the occurrence of an OH---O (water) synthon in the presence of a competing
acceptor, ether moiety, is relatively high. Synthons IV (OH---CN) and V (OH---NO)
exists in form II and form III respectively. All the five synthons occur within the distance
ranges which are consistent with the CSD analysis.
Though EGCG shows profound beneficiary effects on health, it suffers from the
problem of poor bioavailability. This study, on structural features of EGCG, could
potentially provide valuable information for structural modifications, which may change
the physiochemical properties of EGCG. One of the future aspects of this study could be
the design of co-crystals of EGCG. A brief description for co-crystals is provided here.
A broad definition for co-crystal is given by Dunitz as “Crystals containing two or
more components together”. 112 In a more specific way others 113,114 defined co-crystal as
“a multiple component crystal formed between compounds that are solid under ambient
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conditions: at least one component is molecular and forms a supramolecular synthon with
the remaining components”. Co-crystals exhibit different physiochemical properties
(such as bioavailability, solubility) from their starting materials, due to being new and
distinct solid state structures.
To design co-crystals of EGCG co-crystal formers can be chosen based on CSD
analysis. A small survey which represents the competitiveness between aromatic nitrogen
and the carbonyl of an ester group to form a hydrogen bond with the hydroxyl moiety on
phenols is conducted in the CSD. Results have revealed that 36 hits were present
containing hydroxyl, ester, and aromatic nitrogen groups. Out of these 36 hits, 14 hits
contain the OH---N (arom) synthon, 7 hits contain the OH---CO (ester) synthon, and 4 hits
contain the OH---OH synthon. All three synthons occur within the distance range of 2.53.0Å (OH----N (arom)), 2.56-2.94 Å (OH---CO (ester)) and 2.6-3.0 Å (OH---OH)
respectively. The distances are estimated from histograms generated by the CSD. This
study has revealed that the occurrence of the OH----N (arom) synthon is relatively more
favored than other synthons. Therefore compounds like caffeine and theobromine
(which contain aromatic nitrogen) could potentially act as good co-crystal formers.
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